Differential gene expression analysis shows that cephalosporin resistance is intrinsic to Clostridioides difficile strain 630

IF 2.1 4区 医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Lara A. Turello, Amber Consul, Christopher Yip, Shirley Shen, Cale Seymour, Corey Geurink, Israel Alvarado, Ernesto Abel-Santos
{"title":"Differential gene expression analysis shows that cephalosporin resistance is intrinsic to Clostridioides difficile strain 630","authors":"Lara A. Turello, Amber Consul, Christopher Yip, Shirley Shen, Cale Seymour, Corey Geurink, Israel Alvarado, Ernesto Abel-Santos","doi":"10.1038/s41429-024-00795-3","DOIUrl":null,"url":null,"abstract":"Clostridioides difficile infection (CDI) is the most common nosocomial infection in the US. CDI has become a growing concern due to C. difficile’s resistance to several antibiotics, including cephalosporins. Furthermore, patients administered cephalosporins are at higher risk of contracting CDI. Cephalosporins are β-lactam antibiotics, which prevent bacterial cell wall synthesis by inhibiting penicillin-binding proteins (PBPs). β-lactam-resistant bacteria evade these antibiotics by producing β-lactamases or by harboring low-affinity PBPs. A genomic analysis of C. difficile strain 630 identified 31 putative β-lactam resistance genes. Upon cefoxitin exposure, few C. difficile strain 630 putative antibiotic-resistant genes were overexpressed. Most notably, the β-lactamase blaCDD gene was upregulated approximately 600-fold, as previously reported. Deletion of the blaCDD locus did not change in cephalosporin susceptibility. Deletion of the second most upregulated gene, the PBP vanY, was also ineffective at decreasing cephalosporin resistance. Cefoxitin exposure of the C. difficile strain 630ΔblaCDD mutant did not increase upregulation of other putative antibiotic resistance genes compared to wildtype C. difficile strain 630. Transcriptomic analyses of wildtype C. difficile strain 630 exposed to cephradine, cefoxitin, ceftazidime, or cefepime revealed the shared upregulation of a putative heterodimeric ABC transporter encoded by loci CD630_04590 (ABC transporter ATP-binding protein) and CD630_04600 (ABC transporter permease). These genes are genomically located directly downstream of blaCDD (CD630_04580). The deletion mutant CD630_04600 remained resistant to a number of antibiotics. Thus, even though blaCDD, CD630_04590, and CD630_04600 are all upregulated when exposed to cephalosporins, they do not seem to be involved in antibiotic resistance in C. difficile strain 630.","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":"78 2","pages":"113-125"},"PeriodicalIF":2.1000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antibiotics","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41429-024-00795-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Clostridioides difficile infection (CDI) is the most common nosocomial infection in the US. CDI has become a growing concern due to C. difficile’s resistance to several antibiotics, including cephalosporins. Furthermore, patients administered cephalosporins are at higher risk of contracting CDI. Cephalosporins are β-lactam antibiotics, which prevent bacterial cell wall synthesis by inhibiting penicillin-binding proteins (PBPs). β-lactam-resistant bacteria evade these antibiotics by producing β-lactamases or by harboring low-affinity PBPs. A genomic analysis of C. difficile strain 630 identified 31 putative β-lactam resistance genes. Upon cefoxitin exposure, few C. difficile strain 630 putative antibiotic-resistant genes were overexpressed. Most notably, the β-lactamase blaCDD gene was upregulated approximately 600-fold, as previously reported. Deletion of the blaCDD locus did not change in cephalosporin susceptibility. Deletion of the second most upregulated gene, the PBP vanY, was also ineffective at decreasing cephalosporin resistance. Cefoxitin exposure of the C. difficile strain 630ΔblaCDD mutant did not increase upregulation of other putative antibiotic resistance genes compared to wildtype C. difficile strain 630. Transcriptomic analyses of wildtype C. difficile strain 630 exposed to cephradine, cefoxitin, ceftazidime, or cefepime revealed the shared upregulation of a putative heterodimeric ABC transporter encoded by loci CD630_04590 (ABC transporter ATP-binding protein) and CD630_04600 (ABC transporter permease). These genes are genomically located directly downstream of blaCDD (CD630_04580). The deletion mutant CD630_04600 remained resistant to a number of antibiotics. Thus, even though blaCDD, CD630_04590, and CD630_04600 are all upregulated when exposed to cephalosporins, they do not seem to be involved in antibiotic resistance in C. difficile strain 630.

Abstract Image

差异基因表达分析表明,艰难梭菌菌株630对头孢菌素具有内在抗性。
艰难梭菌感染(CDI)是美国最常见的院内感染。由于艰难梭菌对包括头孢菌素在内的多种抗生素产生耐药性,艰难梭菌感染日益受到关注。此外,使用头孢菌素类药物的患者感染 CDI 的风险更高。头孢菌素是β-内酰胺类抗生素,它通过抑制青霉素结合蛋白(PBPs)来阻止细菌细胞壁的合成。耐β-内酰胺细菌通过产生β-内酰胺酶或携带低亲和力的PBPs来逃避这些抗生素。对艰难梭菌 630 株的基因组分析发现了 31 个推测的β-内酰胺耐药基因。暴露于头孢西丁后,艰难梭菌 630 株的少数推定抗生素耐药基因被过度表达。最值得注意的是,β-内酰胺酶 blaCDD 基因上调了约 600 倍,这与之前的报道一致。删除 blaCDD 基因座不会改变对头孢菌素的敏感性。删除第二大上调基因 PBP vanY 也不能有效降低头孢菌素耐药性。与野生型艰难梭菌菌株 630 相比,艰难梭菌菌株 630ΔblaCDD 突变体暴露于头孢西丁后,其他推定抗生素耐药基因的上调并没有增加。对暴露于头孢拉定、头孢西丁、头孢唑肟或头孢吡肟的野生型艰难梭菌 630 株进行转录组分析,发现由 CD630_04590(ABC 转运体 ATP 结合蛋白)和 CD630_04600(ABC 转运体渗透酶)基因座编码的推测异源 ABC 转运体共同上调。这些基因在基因组上位于 blaCDD(CD630_04580)的直接下游。缺失突变体 CD630_04600 仍对多种抗生素具有抗药性。因此,尽管 blaCDD、CD630_04590 和 CD630_04600 在暴露于头孢菌素时都会上调,但它们似乎与艰难梭菌 630 株的抗生素耐药性无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Antibiotics
Journal of Antibiotics 医学-免疫学
CiteScore
6.60
自引率
3.00%
发文量
87
审稿时长
1 months
期刊介绍: The Journal of Antibiotics seeks to promote research on antibiotics and related types of biologically active substances and publishes Articles, Review Articles, Brief Communication, Correspondence and other specially commissioned reports. The Journal of Antibiotics accepts papers on biochemical, chemical, microbiological and pharmacological studies. However, studies regarding human therapy do not fall under the journal’s scope. Contributions regarding recently discovered antibiotics and biologically active microbial products are particularly encouraged. Topics of particular interest within the journal''s scope include, but are not limited to, those listed below: Discovery of new antibiotics and related types of biologically active substances Production, isolation, characterization, structural elucidation, chemical synthesis and derivatization, biological activities, mechanisms of action, and structure-activity relationships of antibiotics and related types of biologically active substances Biosynthesis, bioconversion, taxonomy and genetic studies on producing microorganisms, as well as improvement of production of antibiotics and related types of biologically active substances Novel physical, chemical, biochemical, microbiological or pharmacological methods for detection, assay, determination, structural elucidation and evaluation of antibiotics and related types of biologically active substances Newly found properties, mechanisms of action and resistance-development of antibiotics and related types of biologically active substances.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信